OrbusNeich, a name that has become synonymous with innovation in the medical device industry, is a global leader in the development and manufacture of cardiovascular devices. With a strong commitment to improving patient outcomes and enhancing healthcare provider efficiency, OrbusNeich has been at the forefront of cardiovascular innovation for over two decades.
Founded in 1995, OrbusNeich has its roots deeply embedded in the medical industry. The company's journey began with a simple yet powerful mission: to provide innovative solutions that address unmet clinical needs in cardiovascular medicine. Today, this mission continues to drive OrbusNeich's research and development efforts, resulting in a portfolio of groundbreaking products that have transformed the way cardiovascular diseases are treated worldwide.
OrbusNeich's Innovative Product Portfolio
OrbusNeich's product portfolio is a testament to the company's commitment to innovation and patient care. It includes a range of cardiovascular devices designed to improve patient outcomes and enhance healthcare provider efficiency.
One of the standout products in OrbusNeich's portfolio is the Genous BioEngineered R Stent. This innovative stent is designed to mimic the body's natural healing response, reducing the risk of restenosis and late stent thrombosis. The Genous BioEngineered R Stent has been clinically proven to provide superior outcomes in patients with complex cardiovascular disease.
Genous BioEngineered R Stent
The Genous BioEngineered R Stent is a unique product that leverages OrbusNeich's proprietary Endothelium Progenitor Cell Capture (EPCC) technology. This technology enables the stent to capture and promote the growth of endothelial cells, which are essential for the body's natural healing process. By mimicking the body's natural healing response, the Genous BioEngineered R Stent helps to prevent the formation of blood clots and reduces the risk of restenosis.
Clinical studies have shown that the Genous BioEngineered R Stent provides superior outcomes compared to bare metal stents and other drug-eluting stents. In the GENOUS II trial, for instance, the Genous BioEngineered R Stent demonstrated a significantly lower rate of target lesion failure compared to a bare metal stent at one year.
Other Innovative Products
In addition to the Genous BioEngineered R Stent, OrbusNeich offers a range of other innovative products designed to improve patient outcomes in cardiovascular medicine. These include the Sapphire Balloon Catheter, which is designed to deliver high-pressure inflation for optimal lesion preparation, and the Monorail PTA Dilatation Catheter, which offers a low-profile design for enhanced deliverability.
OrbusNeich's product portfolio also includes the CGuard Embolic Protection System, a unique device designed to prevent distal embolization during carotid artery stenting procedures. The CGuard Embolic Protection System has been clinically proven to reduce the risk of stroke and other complications associated with carotid artery stenting.
OrbusNeich's Commitment to Clinical Research
OrbusNeich's commitment to innovation is underpinned by a strong commitment to clinical research. The company invests heavily in clinical studies to validate the safety and efficacy of its products and to gather real-world evidence of their benefits.
OrbusNeich has participated in numerous clinical trials, including the GENOUS II trial, the ISAR-TEST 4 trial, and the CARENET trial. These trials have provided valuable insights into the performance of OrbusNeich's products in real-world clinical settings and have helped to establish the company's products as gold standards in cardiovascular medicine.
Clinical Trials and Registries
OrbusNeich's commitment to clinical research is reflected in its participation in a wide range of clinical trials and registries. The company has participated in over 100 clinical studies, involving more than 10,000 patients worldwide. These studies have helped to establish the safety and efficacy of OrbusNeich's products and have provided valuable insights into their real-world performance.
OrbusNeich's participation in clinical trials and registries is not just about gathering data. It's also about building relationships with healthcare providers and researchers, fostering collaboration, and driving innovation in cardiovascular medicine.
Real-World Evidence
In addition to clinical trials, OrbusNeich also places a strong emphasis on real-world evidence. The company's products are used in clinical practice around the world, providing a wealth of real-world data that can be used to improve patient outcomes and enhance healthcare provider efficiency.
OrbusNeich's real-world evidence initiatives include the ORBIT registry, which is designed to collect data on the long-term performance of OrbusNeich's products in real-world clinical practice. The ORBIT registry has provided valuable insights into the performance of OrbusNeich's products in a wide range of patient populations and has helped to establish their safety and efficacy in real-world clinical practice.
In the ever-evolving landscape of cardiovascular medicine, OrbusNeich continues to push the boundaries of innovation. With a commitment to improving patient outcomes, enhancing healthcare provider efficiency, and driving innovation through clinical research, OrbusNeich is well-positioned to continue its leadership in the cardiovascular device industry. As we look to the future, we can expect to see more groundbreaking products and innovative solutions from OrbusNeich, further transforming the way cardiovascular diseases are treated worldwide.